ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0136993 | Poly-glutathione peptides composed of (Glu-Cys)n-Gly where n is two to seven. They are biosynthesized by glutathione gamma-glutamylcysteinyltransferase and are found in many PLANTS; YEASTS; and algae. They sequester HEAVY METALS. | phytochelatins|phytochelatin|Phytochelatin | Phytochelatins |
C1522909 | The process whose specific outcome is the progression of the leaf over time, from its formation to the mature structure. [GOC:go_curators] | null | leaf development |
C0007214 | null | null | Cardiotoxin II |
C0007214 | null | null | Cardiotoxin II |
C0242724 | Expanded structures, usually green, of vascular plants, characteristically consisting of a bladelike expansion attached to a stem, and functioning as the principal organ of photosynthesis and transpiration. (American Heritage Dictionary, 2d ed) | Leaf, Plant|leaves|Leave, Plant|Leaves|Leaf|Folium|Plant Leaf|leaf|Plant Leaves|Leaves, NOS|Plant Leave|Leaves, Plant|Leaves (substance) | Plant Leaves |
C0330653 | null | Malus communis|Malus domestica|Malus pumila var. domestica|Tree, Apple|cultivated apple|Pyrus malus|Apple Tree|Malus x domestica|Apple Trees|Trees, Apple|Malus domestica (organism)|Malus pumila auct.|apple tree|Malus sylvestris var. domestica | Malus domestica |
C0282524 | The most common of the microsatellite tandem repeats (MICROSATELLITE REPEATS) dispersed in the euchromatic arms of chromosomes. They consist of two nucleotides repeated in tandem; guanine and thymine, (GT)n, is the most frequently seen. | Dinucleotide Repeat | Dinucleotide Repeats |
C0600493 | The sequence at the 5' end of the messenger RNA that does not code for product. This sequence contains the ribosome binding site and other transcription and translation regulating sequences. | Sequences, mRNA Leader|Sequence, Leader mRNA|5' UTRs|Sequence, mRNA Leader|5'UTR|5'UTRs|UTR, 5'|Untranslated Regions, 5'|mRNA Leader Sequence|5' Untranslated Region|UTRs, 5'|5' UTR|Leader mRNA Sequence|mRNA Sequence, Leader|Untranslated Region, 5'|Leader Sequence, mRNA|mRNA Sequences, Leader|Region, 5' Untranslated|Leader Sequences, mRNA|Sequences, Leader mRNA|Leader mRNA Sequences|Regions, 5' Untranslated|mRNA Leader Sequences | 5' Untranslated Regions |
C0242326 | null | 15th Cent. Medicine | Medicine, 15th Cent. |
C0242326 | null | 15th Cent. Medicine | Medicine, 15th Cent. |
C0671340 | null | nudix hydrolase | nudix hydrolases |
C0242326 | null | 15th Cent. Medicine | Medicine, 15th Cent. |
C0242326 | null | 15th Cent. Medicine | Medicine, 15th Cent. |
C0036079 | A beta hydroxy acid that occurs as a natural compound in plants. It has direct activity as an anti-inflammatory agent and acts as a topical antibacterial agent due to its ability to promote exfoliation. | O-carboxyphenol|o Hydroxybenzoic Acid|Salicylic acid|Acid, 2-Hydroxybenzoic|ortho-Hydroxybenzoic Acid|ácido salicílico|ortho Hydroxybenzoic Acid|Acid, Salicylic|Acidum salicylicum|Salicylic Acid|o-Hydroxybenzoic Acid|Salicylic acid-containing product|2-Hydroxybenzoic Acid|2-Hydroxybenzoic acid|Acid, ortho-Hydroxybenzoic|salicylic acid|Salicylic acid, NOS|2-Carboxyphenol|SALICYLIC ACID|salicylic|2 Hydroxybenzoic Acid|Acid, o-Hydroxybenzoic|Product containing salicylic acid (medicinal product)|Salicylic acid (substance)|O-hydroxybenzoic acid | salicylic acid |
C0884951 | A plant genus of the family Plantaginaceae. Members contain DEFICIENS PROTEIN. | snapdragon|Snapdragon|snapdragons|Antirrhinum|Snapdragons | Antirrhinum |
C0077678 | A diverse class of enzymes that interact with UBIQUITIN-CONJUGATING ENZYMES and ubiquitination-specific protein substrates. Each member of this enzyme group has its own distinct specificity for a substrate and ubiquitin-conjugating enzyme. Ubiquitin-protein ligases exist as both monomeric proteins multiprotein complexes. | Ligase E3, Ubiquitin-Protein|Ligase, E3|E3 Ubiquitin Transferase|Ubiquitin Ligase, E3|ubiquitin protein ligase|Ubiquitin Ligase E3|E3 Ubiquitin-Protein Ligase|E3 Ubiquitin-Protein Transferase|Ubiquitin-Protein Ligases|Ubiquitin Protein Ligases|Ligase, Ubiquitin-Protein|Ligases, Ubiquitin-Protein|Ligase E3, Ubiquitin|E3 Ligase|Ligase, E3 Ubiquitin|Ubiquitin Protein Ligase E3|Ubiquitin-Protein Ligase E3|E3 ligase|E3 Ubiquitin Ligase|Ubiquitin Protein Ligase|Ubiquitin--protein ligase|Ubiquitin--protein ligase (substance)|Ubiquitin-Protein Ligase | ubiquitin-protein ligase |
C0376452 | Addition of methyl groups to DNA. DNA methyltransferases (DNA methylases) perform this reaction using S-ADENOSYLMETHIONINE as the methyl group donor. | Methylations, DNA|DNA Methylations|Methylation, DNA|DNA Methylation Process|DNA Methylation|DNA methylation|dna methylation | DNA Methylation |
C0008520 | The thin, highly vascular membrane covering most of the posterior of the eye between the RETINA and SCLERA. | Choroid|Choroids|Choroid, NOS|CHOROID|EYE, CHOROID|choroidea|choroid|choroid eye|Choroidal structure (body structure)|Choroidal structure|Choroid of eye|Choroidea | Choroid |
C0008520 | The thin, highly vascular membrane covering most of the posterior of the eye between the RETINA and SCLERA. | Choroid|Choroids|Choroid, NOS|CHOROID|EYE, CHOROID|choroidea|choroid|choroid eye|Choroidal structure (body structure)|Choroidal structure|Choroid of eye|Choroidea | Choroid |
C0331103 | null | Rauwolfia serpentinas|serpentina, Rauwolfia|rauvolfia serpentina|Rauvolfia serpentina (organism)|Rauvolfia serpentinas|rauwolfia serpentina|devilpepper|Rauwolfia serpentina|serpentina, Rauvolfia|Rauvolfia serpentina | Rauvolfia serpentina |
C0075326 | null | Strictosidine synthase (substance)|strictosidine synthetase|Strictosidine synthase | Strictosidine synthase |
C0001888 | An alkaloid found in the root of RAUWOLFIA SERPENTINA, among other plant sources. It is a class Ia antiarrhythmic agent that apparently acts by changing the shape and threshold of cardiac action potentials. | AJMALINE|Ajmalin|(5aR,6S,8S,10S,11S,11aS,12aR,13R)-5-methyl-5a,6,8,9,10,11,11a,12-octahydro-5H-6,10:11,12a-dimethanoindolo[3,2-b]quinolizine-8,13-diol|Ajmalan-17,21-diol, (17R,21alpha)-|ajmaline|(+)-Ajmaline|Ajmaline | ajmaline |
C0599132 | A photosystem that contains a pheophytin-quinone reaction center with associated accessory pigments and electron carriers. In cyanobacteria and chloroplasts, in the presence of light, PSII functions as a water-plastoquinone oxidoreductase, transferring electrons from water to plastoquinone, whereas other photosynthetic bacteria carry out anoxygenic photosynthesis and oxidize other compounds to re-reduce the photoreaction center. [GOC:ds, GOC:mah, ISBN:0943088399, PMID:9821949] | photosystem II | Photosystem II |
C0996936 | A plant genus of the family SOLANACEAE. Members contain steroidal glycosides. | Petunias | Petunia |
C1136227 | A growth from a pollen grain down into the flower style which allows two sperm to pass, one to the ovum within the ovule, and the other to the central cell of the ovule to produce endosperm of SEEDS. | Pollen tube|pollen tube|Pollen Tubes|Tube, Pollen|Tubes, Pollen | Pollen Tube |
C0599871 | null | desaturase | desaturase |
C0599871 | null | desaturase | desaturase |
C0029235 | A living thing, such as an animal, a plant, a bacterium, or a fungus. | living organisms|live organisms|Organisms|BiologicEntity|living organism|Living organism, NOS|Organism - attribute|Organism|Organism (attribute)|Organism (organism)|organism|Organismal|LIVING ORGANISMS IN GENERAL|LIVING ORGANISMS|LIVING ORGANISMS: GENERAL TERMS|organisms|living system | Organism |
C0054455 | Cell surface proteins that bind calcitonin and trigger intracellular changes which influence the behavior of cells. Calcitonin receptors outside the nervous system mediate the role of calcitonin in calcium homeostasis. The role of calcitonin receptors in the brain is not well understood. | Receptor, Calcitonin|Receptors, Calcitonin|Calcitonin Receptor|Calcitonin Receptors | Calcitonin Receptor |
C1257858 | null | Cell, COS-7|COS 7 Cells|Cells, COS-7|COS-7 Cell | COS-7 Cells |
C0008109 | An individual that contains cell populations derived from different zygotes. | chimeric|Chimera|chimera|Chimeras|chimeras|Chimeric | Chimera organism |
C0682972 | The largest family of cell surface receptors involved in SIGNAL TRANSDUCTION. They share a common structure and signal through HETEROTRIMERIC G-PROTEINS. | GPCR|G-protein-associated receptor|G Protein-Complex Receptors|G Protein Coupled Receptors|G-Protein Coupled Receptor|coupled g protein receptor|G-Protein-Coupled Receptors|Receptors, G-Protein-Coupled|G-protein-coupled receptors|G protein coupled receptor|g protein coupled receptor|g protein coupled receptors|G Protein Coupled Receptor|G Protein-Coupled Receptor|G Protein-Complex Receptor|Receptors, G Protein Coupled|coupled g protein receptors | G-Protein-Coupled Receptors |
C1510486 | An imaging test that measures bone density (the amount of bone mineral contained in a certain volume of bone) by passing x-rays with two different energy levels through the bone. It is used to diagnose osteoporosis (decrease in bone mass and density). | dual energy x-ray absorptiometric scan|DEXA - dual energy X-ray absorptiometry|DPX Absorptiometry|DXA SCAN|bone mineral density scan|dual energy x-ray absorptiometry|DEXA|Dual X-Ray Absorptiometry|DEXA Scan|X Ray Absorptiometry, Dual Energy|X-Ray Absorptiometry, Dual|DXA|DEXA scan|Dual energy X-ray absorptiometry (procedure)|Dual energy X-ray absorptiometry|dxa|BMD scan|Absorptiometries, DPX|Dual Energy X-ray Absorptiometry|Absorptiometry, Dual X Ray|dual x-ray absorptometry|Dual X Ray Absorptiometry|dual-energy x-ray absorptiometry (DXA) scan|dual energy x-ray absorptometry|Absorptiometry, Dual-Energy X-Ray|Dual Energy X Ray Absorptiometry|Absorptiometry, Dual Energy X Ray|dual-energy x-ray absorptiometry|X-Ray Absorptiometry, Dual-Energy|Absorptiometry, DPX|Dual X-Ray Absorptometry|Dual-Energy X-Ray Absorptiometry|Absorptiometry, Dual X-Ray|dual x-ray absorptiometry|Dual-energy X-ray absorptiometry|Dual X-ray Absorptiometry | Dual-Energy X-Ray Absorptiometry |
C0055600 | null | null | CHOP-VP16 protocol |
C0007222 | Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. | Cardiovascular system--Diseases|Disorder of cardiovascular system (disorder)|Cardiovascular disease|CARDIOVASCULAR DISORDER|Disease or syndrome of cardiovascular system|cardiovascular disease|Cardiovascular disease, NOS|Disorder of Cardiovascular System|CVD - cardiovascular disease|Disease, Cardiovascular|DISEASES OF THE CARDIOVASCULAR SYSTEM|Cardiovascular Diseases|CVD, NOS|cardiovascular system disease|Diseases and Syndromes of Cardiovascular System|Diseases, Cardiovascular|CARDIOVASCULAR DISORDERS: GENERAL TERMS|Cardiovascular Disease|CARDIOVASCULAR DISORDERS|Cardiovascular disease, unspecified|cardiovascular disorders|Cardiovascular Disease (CVD)|Disease of cardiovascular system, NOS|Cardiovascular disorder|Cardiovascular disorder, NOS|DISORDER CARDIOVASCULAR (NOS)|Cardiovascular system disease|cardiovascular diseases|Cardiovascular Disorder|CVS disease - cardiovascular system disease|Disorder of cardiovascular system|CVD|cardiovascular system diseases|DISEASES AFFECTING THE ENTIRE CARDIOVASCULAR SYSTEM|cardiovascular disorder|CARDIOVASCULAR DISORDER (NOS)|General Cardiovascular System Diseases and Syndromes | Cardiovascular Diseases |
C0011860 | A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity. | Diabetes Mellitus, Type II|diabetes type ii|Diabetes mellitus Type II|maturity onset diabetes|Non-Insulin Dependent Diabetes|Adult Onset Diabetes|NCDMM|Diabetes mellitus (NIDDM)|MATURITY-ONSET DIABETES|Type II Diabetes|Non-Insulin Dependent Diabetes Mellitus|DIABETES MELLITUS (ADULT ONSET)|Noninsulin-dependent diabetes mellitus|type II diabetes|adult onset diabetes|ADULT ONSET DIABETES MELLITUS|Maturity-Onset Diabetes|Slow-Onset Diabetes Mellitus|Type II Diabetes Mellitus|Diabetes Mellitus, Ketosis Resistant|Non-insulin dependent diabetes mellitus|Diabetes Mellitus, Adult-Onset|Maturity Onset Diabetes Mellitus|Diabetes mellitus type 2 (disorder)|AODM|diabetes mellitus type ii|Noninsulin-dependent diabetes|diabetes mellitus type 2|noninsulin dependent diabetes mellitus|Type II diabetes mellitus|Diabetes mellitus, type II|late onset diabetes|Diabetes mellitus, Type 2|Adult-Onset Diabetes Mellitus|Diabetes Mellitus, Noninsulin-Dependent|T2DM - Type 2 Diabetes mellitus|NIDDM diabetes mellitus|DIABETES MELLITUS, TYPE II|Diabetes Mellitus, Maturity-Onset|diabetes, type ii|Maturity onset diabetes|Type II diabetes|Diabetes Mellitus, Stable|non-insulin dependent diabetes|Maturity-Onset Diabetes Mellitus|Diabetes mellitus type 2|Adult-Onset Diabetes|adult onset diabetes mellitus|Diabetes Mellitus, Slow-Onset|diabete type 2|Diabetes Mellitus, Non Insulin Dependent|Non-insulin-dependent diabetes|Diabetes mellitus, adult onset type|Noninsulin-Dependent Diabetes Mellitus|type II diabetes mellitus|Noninsulin Dependent Diabetes|Diabetes Mellitus, Adult Onset|Ketosis-Resistant Diabetes Mellitus|Type 2 Diabetes Mellitus|Diabetes, Maturity-Onset|NONINSULIN-DEPENDENT DIABETES MELLITUS|Diabetes Mellitus, Non-Insulin-Dependent|Non-Insulin-Dependent Diabetes Mellitus|DIABETES MELLITUS, TYPE 2|Maturity Onset Diabetes|MODY|Non-insulin dependent diabetes|type 2 diabetes|Type 2 Diabetes Mellitus Non-Insulin Dependent|DIABETES MELLITUS, NON-INSULIN DEPENDENT|Type 2 diabetes mellitus|Diabetes Mellitus, Ketosis-Resistant|Diabetes mellitus, noninsulin-dependent|DIABETES MELLITUS, NONINSULIN-DEPENDENT|Noninsulin dependent diabetes mellitus|Diabetes Mellitus, Type 2|Diabetes, Type 2|non-insulin dependent diabetes mellitus|aodm|diabetes type 2|niddm|Diabetes Type 2|Diabetes Mellitus, Noninsulin Dependent|T2D|Diabetes Mellitus, Slow Onset|type 2 diabetes mellitus|Noninsulin Dependent Diabetes Mellitus|Type 2 Diabetes|DIABETES, ADULT ONSET|DIABETES, MATURITY ONSET|NIDDM|MOD|Type 2 diabetes|DIABETES, KETOSIS RESISTANT|Stable Diabetes Mellitus|Diabetes Mellitus, Maturity Onset|Diabetes mellitus type II|ketosis resistant diabetes|type ii diabetes mellitus | Diabetes Mellitus, Non-Insulin-Dependent |
C0021655 | Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. | Insulin resistance (disorder)|Insulin resistance|Insulin Resistance|Drug resistance to insulin|insulin resistance|Drug resistance to insulin (disorder)|INSULIN RESISTANCE|Body fails to respond to insulin|Resistance, Insulin | Insulin Resistance |
C0136120 | A lipid droplet protein that is expressed primarily by ADIPOCYTES of WHITE ADIPOSE TISSUE and BROWN ADIPOSE TISSUE. It co-localizes with MACROPHAGES and FOAM CELLS of artherosclerotic lesions and stabilizes LIPID DROPLETS by inhibiting HORMONE SENSITIVE LIPASE. It may also protect TRIGLYCERIDES against hydrolysis within the PLASMA MEMBRANE and modulate CHOLESTEROL ESTER HYDROLASE activity. | Perilipin Protein|PERI Protein|Perilipin B Protein|Plin Protein|Protein, Perilipin B|Perilipin-1|Protein, Perilipin|Protein, Perilipin A|Perilipin|Perilipin 1|Protein, PERI|Perilipin A Protein|Protein, Plin | Perilipin-1 |
C0299583 | Leptin (167 aa, ~16 kDa) is encoded by the human LEP gene. This protein is secreted by adipocytes and plays a role in the regulation of both appetite and body fat stores. | Gene Product, Ob|Leptin (substance)|Obese Gene Product|Ob Protein|Leptin|leptins|leptin|Gene Product, Obese|Ob Gene Product|Obese Protein|Obesity Factor | leptin |
C0389071 | A 30-kDa COMPLEMENT C1Q-related protein, the most abundant gene product secreted by FAT CELLS of the white ADIPOSE TISSUE. Adiponectin modulates several physiological processes, such as metabolism of GLUCOSE and FATTY ACIDS, and immune responses. Decreased plasma adiponectin levels are associated with INSULIN RESISTANCE; TYPE 2 DIABETES MELLITUS; OBESITY; and ATHEROSCLEROSIS. | Adipose Most Abundant Gene Transcript 1|Adipocyte, C1q and Collagen Domain Containing Protein|apM 1 Protein|adiponectin|Adiponectin|Adiponectin (substance)|apM-1 Protein|ACRP30 Protein|Adipocyte Complement Related Protein 30 kDa|Adipocyte Complement-Related Protein 30-kDa | Adiponectin |
C1563740 | null | Abdominal Visceral Fats|Adipose Tissue, Visceral|Abdominal Visceral Fat|Fats, Abdominal Visceral|Visceral Fats|Fats, Visceral|Fat, Abdominal Visceral|Fat, Visceral|Visceral Adipose Tissue | Visceral Fat |
C0162597 | Connective tissue cells of an organ found in the loose connective tissue. These are most often associated with the uterine mucosa and the ovary as well as the hematopoietic system and elsewhere. | Stromal Cells|Cells, Stromal|stromal cells|Stromal Cell|Cell, Stromal|stromal cell|Stromal cell | Stromal Cells |
C0021641 | A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). | Unmodified insulin preparation|regular insulin|Insulin|insulin|insulin regular|Product containing insulin (product)|insulin preparations|insulins|Regular Insulin|Regular insulin preparation|insulin products|Insulin, Soluble|insulin preparation|insulin product|INSULIN PREPARATIONS|Insulin (substance)|Insulin, Regular|Soluble Insulin|Insulin preparation, NOS|Insulin-containing product | Insulin |
C0055600 | null | null | CHOP-VP16 protocol |
C0034865 | Production of new arrangements of DNA by various mechanisms such as assortment and segregation, CROSSING OVER; GENE CONVERSION; GENETIC TRANSFORMATION; GENETIC CONJUGATION; GENETIC TRANSDUCTION; or mixed infection of viruses. | Recombinations, Genetic|recombinations|dna recombination|Genetic recombination (finding)|genetic recombination|DNA recombination|Recombinations|recombination|DNA Recombination Process|Recombination|Genetic recombination|Genetic Recombination|DNA Recombination|Genetic Recombinations|DNA recombination (naturally occurring) | Recombination, Genetic |
C0282472 | A species of AVIPOXVIRUS, subfamily CHORDOPOXVIRINAE. Canarypox virus vectors are used in vaccine and immunotherapy research. | Canarypox virus (organism)|Canarypox|canarypox virus|Canarypox viruses|Canarypox Virus|Canarypox virus|Avipoxvirus clade B1|Canary pox virus | Canarypox virus |
C0282204 | a person having origins in any of the original peoples of the Americas, or who maintains cultural identification through tribal affiliation or community recognition. | NATIVE AMERICAN|Americans, Native|Native American|American, Native|native americans|Native Americans | Native Americans |
C0001175 | An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. | Acquired Immuno-Deficiency Syndrome|AIDS, Acquired Immunodeficiency Syndrome|Acquired Immuno-Deficiency Syndromes|acquired immunodeficiency syndrome (AIDS)|hiv-infection/aids|autoimmune deficiency syndrome|Acquired Immunodeficiency Syndrome|Acquired immune deficiency syndrome|acquired immunodeficiency syndrome|Syndromes, Acquired Immunodeficiency|Acquired immune deficiency syndrome (disorder)|aids|Acquired immune deficiency syndrome, NOS|AIDS HIV infections|Syndrome, Acquired Immuno-Deficiency|AIDS HIV infection|Syndromes, Acquired Immuno-Deficiency|AUTOIMMUNE DEFICIENCY SYNDROME|Immunologic Deficiency Syndrome, Acquired|Immunodeficiency due to human immunodeficiency virus infection|Immuno-Deficiency Syndrome, Acquired|HIV/AIDS|AIDS - Acquired immunodeficiency syndrome|ACQUIRED IMMUNE DEFICIENCY SYNDROME|Immuno-Deficiency Syndromes, Acquired|IMMUNE DEFICIENCY SYNDROME ACQUIRED AIDS|AIDS, NOS|AIDS disorders|Syndrome, Acquired Immunodeficiency|sida|Immunodeficiency Syndromes, Acquired|Acquired Immune Deficiency|Acquired immunodeficiency syndrome|acquired immune deficiency syndrome|Acquired Immunodeficiency Syndromes|Acquired Immune Deficiency Syndrome|AIDS|Acquired immunodeficiency syndrome, NOS|Acquired Immunodeficiency Disease|Acquired Immunodeficiency Syndrome, AIDS|Immunodeficiency Syndrome, Acquired|Acquired Immuno Deficiency Syndrome|Acquired immune deficiency syndrome (AIDS)|IMMUNE DEFICIENCY SYNDROME ACQUIRED <AIDS> | Acquired Immunodeficiency Syndrome |
C0009905 | Compounds, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. The hormones are generally estrogen or progesterone or both. | Oral Contraceptives|contraceptive pills for birth control|Oral contraceptives|birth control pill|ORAL CONTRACEPTIVE PREPARATIONS|Oral contraceptive drug|Contraceptive pills for birth control|Oral contraceptive agent|oral contraceptive pill|birth contraceptives control pills|Contraceptives, Oral|birth control pill contraceptive|oral contraceptives|Oral contraceptive, NOS|Oral contraceptive preparation, NOS|birth contraceptive control pills|Oral contraceptive agent, NOS|oral contraceptive|birth control pills|Birth control pill|Oral Contraceptive|Oral contraceptive drug, NOS|Birth control pill, NOS | Contraceptives, Oral |
C0596497 | a place of education including usually the first five to the first six grades and often a kindergarten. | elementary school|elementary schools | Elementary Schools |
C0026606 | Body movements of a human or an animal as a behavioral phenomenon. | Physical activity|Physical behavior|Motor Behavior|Motor behavior, NOS|Physical behaviour, NOS|Motor behaviour|activity|Motor behavior|Engaged in physical activity|Physical Activities|physical activities|PHYSICAL ACTIVITIES|Physical behavior, NOS|Motor behaviour, NOS|Activity, Motor|Engaged in physical activity, NOS|Motor Activity|Physical behaviour|Physical activity (observable entity)|Motor activity|motor activity|physical activity|Motor behavior (observable entity)|Motor activity, NOS|motor behavior|motor activities|Physical Activity|Motor Activities|Activities, Motor | Physical activity |
C0026605 | Those factors which cause an organism to behave or act in either a goal-seeking or satisfying manner. They may be influenced by physiological drives or by external stimuli. | Motivation finding|motivations|Motivation, NOS|motivation|Motivation (observable entity)|Motivation finding (finding)|Motivations|Motivation|Motive | Motivation |
C0020008 | Large hospitals with a resident medical staff which provides continuous care to maternity, surgical and medical patients. | general hospitals|general hospital|General Hospital|General Hospitals|Hospital, General | Hospitals, General |
C0457801 | An individual who does not drink at the present time. This is a heterogeneous group comprising both lifelong teetotallers and ex-drinkers. | abstinent|Non-Drinker|Teetotaller|Abstainer|Abstinent|Non - drinker|Never drinks|Current non-drinker of alcohol (finding)|Non - drinker alcohol|Current non-drinker of alcohol|Does not drink alcohol|non drinker|alcohol does drinking|Non-drinker, NOS|Nondrinker|Non-drinker of alcoholic beverage, NOS | Current non-drinker of alcohol |
C0021081 | Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. | immunosuppressants|Immunosuppressants|Immunosuppressant Agents|Agents, Immunosuppressive|Immunosuppressant|Immunosuppressant (substance)|Immunosuppressive Agents|immunosuppressant|immunosuppressives|immunosuppressive agents|Immunosuppressive agents|Immunosuppressive agent, NOS|immunosuppressive|IMMUNOSUPPRESSANTS|Immunosuppressant agent, NOS|immune suppressants|immune suppressant|IMMUNE SUPPRESSANTS|Immunosuppressant agent|Medicinal product acting as immunosuppressant (product) | Immunosuppressive Agents |
C0277556 | The return of a disease after a period of remission. | recurrent disease|Relapsed Disease|Relapse|Relapse, Site Not Specified|DISEASE RELAPSE|Recurrent disease, NOS|RELAPSED DISEASE|RECURRENT DISEASE|Recurrent disease (disorder)|Recurrent Disease|relapse|disease recurrent|Disease in relapse|Diseases--Relapse|Recurrent disease | Recurrent disease |
C0232493 | Pain that is localized to the region of the upper abdomen immediately below the ribs. [https://www.healthgrades.com/symptoms/epigastric-pain, ORCID:0000-0001-5208-3432] | epigastric pain|Abdominal pain, epigastric|EPIGASTRIC ABDOMINAL PAIN|epigastric ache|Epigastric pain|Epigastrium pain|PAIN EPIGASTRIC|Epigastric pain (finding) | Epigastric pain |
C0920367 | An imaging method using LASERS that is used for mapping subsurface structure. When a reflective site in the sample is at the same optical path length (coherence) as the reference mirror, the detector observes interference fringes. | OCT Tomography|optical coherence tomography|coherence optical tomography|Tomography, OCT|Optical coherence tomography|Optical coherence tomography (procedure)|Coherence Tomography, Optical|OCT|Optical Coherence Tomography|Tomography, Optical Coherence|OCT - Optical coherence tomography|Doppler OCT|OPTICAL COHERENCE TOMOGRAPHY | Tomography, Optical Coherence |
C0238598 | A person between 19 and 24 years of age. | Young Adults|Young adults|Young Adult|Adults, Young|young adult|Adult Youth|Adult, Young|ADULT, YOUNG | Young Adult |
C0546275 | Sparse and small myenteric ganglia [] | Hypoganglionosis | Hypoganglionosis |
C0021390 | Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS. | IBD - Inflammatory bowel disease|bowel diseases inflammatory|disease inflammatory bowel|Inflammatory Bowel Disease|Inflammatory bowel disease|Bowel Diseases, Inflammatory|Inflammatory bowel diseases|Chronic enteropathy|Chronic enteritis|inflammatory bowel diseases|Inflammatory Bowel Diseases|IRRITABLE BOWEL DISEASE|Autoimmune Bowel Disorder|Inflammatory bowel disease (disorder)|IBD|INFLAMMATORY BOWEL DISEASE|inflammatory bowel disease|Inflammatory bowel disease, NOS|bowel disease inflammatory | Inflammatory Bowel Diseases |
C0341335 | Inflammation of the colon that is caused by Cytomegalovirus. | CMV - Cytomegalovirus colitis|Cytomegalovirus colitis|colitis cytomegalovirus|cmv colitis|Cytomegaloviral colitis (disorder)|cytomegalovirus colitis|Cytomegalovirus Colitis|CMV Colitis | Cytomegaloviral colitis |
C0000324 | A group of enzymes that catalyze the reversible reduction-oxidation reaction of 20-hydroxysteroids, such as from a 20-ketosteroid to a 20-alpha-hydroxysteroid (EC 1.1.1.149) or to a 20-beta-hydroxysteroid (EC 1.1.1.53). | Hydroxysteroid Dehydrogenases, 20|Dehydrogenases, 20 Hydroxysteroid|20 Hydroxysteroid Dehydrogenases|Dehydrogenases, 20-Hydroxysteroid | 20-Hydroxysteroid Dehydrogenases |
C0011168 | Difficulty in SWALLOWING which may result from neuromuscular disorder or mechanical obstruction. Dysphagia is classified into two distinct types: oropharyngeal dysphagia due to malfunction of the PHARYNX and UPPER ESOPHAGEAL SPHINCTER; and esophageal dysphagia due to malfunction of the ESOPHAGUS. | Deglutition disorder|DYSPHAGIA|Disorders, Deglutition|Dysphagia (disorder)|difficult swallowing|deglutition disorders|deglutition disorder|Deglutition Disorder|SWALLOWING DIFFICULT|SWALLOWING DIFFICULTY|Dysphagia, NOS|dysphagias|Difficulty in swallowing NOS|Swallowing Disorders|Difficulty swallowing (finding)|Deglutition Disorders|Cannot get food down|difficulty in swallowing|Difficulty Swallowing|DEGLUTITION DISORDER|Can't get food down|SWALLOWING DISORDER|swallowing difficulty|dysphagia|Dysphagia|DISORDER DEGLUTITION|Difficulty in swallowing|Swallowing difficult|Deglutition disorders|Difficulties swallowing|swallowing disorder|Swallowing difficulties (dysphagia)|Difficulty swallowing|Swallowing difficulties|Dysphagia, unspecified|Swallowing Disorder|Poor swallowing|Swallowing difficulty | Deglutition Disorders |
C0038356 | Tumors or cancer of the STOMACH. | gastric tumors|Neoplasm, Gastric|Tumor of stomach|Neoplasm of stomach|gastric neoplasms|stomach tumor or cancer|Stomach tumor|gastric tumor|Stomach Tumor|Neoplasm of the stomach|cancer stomach tumors|tumor gastric|Stomach Neoplasm|Tumour of stomach|stomach tumors|Gastric Tumor|Gastric mass|gastric neoplasm|Gastric Neoplasms|stomach neoplasms|stomach neoplasm|Gastric tumor|Neoplasms, Stomach|stomach tumour|neoplasm of stomach|stomach tumor|Stomach--Tumors|Tumor of the Stomach|Gastric Neoplasm|gastric mass|of stomach tumor|Neoplasm of the Stomach|stomach tumours|neoplasm gastric|GASTRIC TUMOR|Stomach Neoplasms|Neoplasm of stomach (disorder)|Neoplasia of the stomach|Neoplasm, Stomach|Tumor of Stomach|Neoplasms, Gastric|Neoplasm of Stomach|tumor of stomach | Stomach Neoplasms |
C0024623 | A primary or metastatic malignant neoplasm involving the stomach. | Gastric cancer|Malignant Tumor of the Stomach|Cancers, Stomach|Gastric Cancers|Gastric Cancer|Cancers, Gastric|Stomach Cancer|malignant neoplasm of stomach|Cancer, Gastric|Malignant Gastric Tumor|Malignant gastric tumor|Malignant tumour of stomach|Malignant Neoplasm of the Stomach|Cancer of the Stomach|Malignant neoplasm of stomach, unspecified site|Stomach Cancers|Cancer of Stomach|Malignant tumor of stomach (disorder)|Malignant tumor of stomach|Malignant neoplasm of stomach, NOS|Stomach (gastric) cancer|GASTRIC CANCER|gastric cancers|Malignant neoplasm of stomach, unspecified|stomach ca|Stomach--Cancer|Malignant Neoplasm of Stomach|Cancer, Stomach|gastric cancer|stomach cancers|stomach cancer|Malignant neoplasm of stomach|Cancer of stomach|Malignant Tumor of Stomach|Malignant Gastric Neoplasm|cancer of the stomach|Stomach cancer|CA - Cancer of stomach|cancer of stomach | Malignant neoplasm of stomach |
C0012817 | A pouch or sac developed from a tubular or saccular organ, such as the GASTROINTESTINAL TRACT. | DIVERTICULUM|Diverticulum (morphologic abnormality)|diverticulums|Diverticula|DIVERTICULA|diverticula|diverticulum|Diverticulum, NOS|Diverticulum | Diverticulum |
C0024141 | A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. | LUPUS, ERYTHEMATOSUS, SYSTEMIC|Systemic Lupus Erythematosus|LUPUS ERYTHEMATOSUS, SYSTEMIC|DISSEMINATED LUPUS ERYTHEMATOSUS|SYNDROME DISSEMINATED LUPUS ERYTHEMATOSIS|lupus syndrome|erythematosis lupus systemic|LUPUS SYNDROME|SYSTEMIC LUPUS ERYTHEMATOSIS|systemic lupus erythematosus (SLE)|lupus|lupus erythematosus disseminatus|lupus erythematosis|systemic lupus erythematosus|Lupus Erythematosus, Systemic|Lupus erythematosus, disseminated|LUPUS ERYTHEMATOSIS DISSEMINATED|SYNDROME LUPUS|SYSTEMIC LUPUS ERYTHEMATOSUS|LUPUS ERYTHEMATOSIS (NOS)|SLE|disseminated lupus erythematosus|lupus syndromes|SLE - Systemic lupus erythematosus|LE SYNDROME|LUPUS ERYTHEMATOSUS SYSTEMIC|Lupus Erythematosus Disseminatus|les syndrome|Disseminated lupus erythematosus|Systemic lupus erythematosus|Lupus erythematosus, Systemic|Lupus erythematosus, systemic|LUPUS ERYTHEMATOSUS, DISSEMINATED|syndrome lupus|sles|SLE - Lupus Erythematosus, Systemic|le syndrome|Systemic lupus erythematosus (disorder) | Lupus Erythematosus, Systemic |
C1565489 | Diminished kidney function. | Kidney Insufficiencies|impaired renal function|renal insufficiencies|Renal impairment|function impaired renal|renal insufficiency|Renal dysfunction|Renal Insufficiency|kidney insufficiency|Renal insufficiency|impairment renal|INSUFFICIENCY RENAL|renal impairment|Kidney Insufficiency|Renal Insufficiencies|Insufficiency, Kidney|Renal impairment (disorder)|RENAL INSUFFICIENCY|Impaired renal function|Renal Impairment|Kidney Impairment|impairments renal | Renal Insufficiency |
C0393022 | A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS. | rituximab|Rituximab|Product containing rituximab (medicinal product)|Rituximab-containing product|Rituximab CD20 Antibody|Rituximab (substance)|CD20 Antibody, Rituximab|RITUXIMAB|C2B8 Monoclonal Antibody|riTUXimab|Chimeric Anti-CD20 Antibody|Rituximab ABBS | rituximab |
C0003241 | Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS). | Antibody|Antibody-containing product|Antibodies|antibodies|Antibody, NOS|antibody|Ab|Antibody (substance)|Product containing antibody (product) | Antibodies |
C0034783 | Cell-surface proteins that bind epinephrine and/or norepinephrine with high affinity and trigger intracellular changes. The two major classes of adrenergic receptors, alpha and beta, were originally discriminated based on their cellular actions but now are distinguished by their relative affinity for characteristic synthetic ligands. Adrenergic receptors may also be classified according to the subtypes of G-proteins with which they bind; this scheme does not respect the alpha-beta distinction. | adrenoceptor|adrenergic receptors|Adrenoceptor|Adrenergic receptor|adrenoceptors|Catecholamine Receptor|Receptors, Epinephrine|Adrenaline--Receptors|Receptors, Adrenergic|adrenoreceptor|adrenergic receptor sites|Adrenoceptors|Epinephrine Receptors|Adrenergic Receptors|Norepinephrine Receptor|Adrenergic receptor (substance)|Adrenergic receptor site|adrenergic receptor|Receptor, Adrenergic|Adrenergic Receptor | Adrenergic Receptor |
C0027769 | An uneasy psychological state; the anxious feeling you have when you have the jitters. | TENSION NERVOUS|NERVOUS TENSION|nervi|Nervousness|nervousness|nervy|feeling jittery|Feeling of Nervousness|nervous tension|Nervous|nervous|NERVOUSNESS | Nervousness |
C0085568 | A lesion in the skin and subcutaneous tissues due to infections by MYCOBACTERIUM ULCERANS. It was first reported in Uganda, Africa. | Infection, Mycobacterium ulcerans|Buruli Ulcer|Ulcer, Buruli|Mycobacterium ulcerans infection|Disease, Buruli Ulcer|Buruli Ulcer Disease|Searles's ulcer|Infections, Mycobacterium ulcerans|SEARL ULCER|Skin infection by Mycobacterium ulcerans|Ulcer Diseases, Buruli|MYCOBACTERIUM ULCERANS INFECTION|BURULI ULCER|Ulcer Disease, Buruli|Buruli Ulcer Diseases|Diseases, Buruli Ulcer|Buruli ulcer|Mycobacterium ulcerans Infection|Cutaneous mycobacterium ulcerans infection|Infection due to Mycobacterium ulcerans|buruli ulcer|Mycobacterium ulcerans Infections|Buruli ulcer (disorder) | Buruli Ulcer |
C0026918 | Infections with bacteria of the genus MYCOBACTERIUM. | mycobacterium infection|Mycobacterial Infection|Mycobacterial infections|Mycobacterial diseases|Infection due to mycobacteria|Mycobacterial disease|Infections, Mycobacterium|mycobacterial infection|MYCOBACTERIOSES|Infection, Mycobacterium|Mycobacterial infectious disease|Mycobacteriosis (disorder)|Mycobacteriosis, NOS|infections mycobacterial|Mycobacterial infection|Mycobacterium Infections|Mycobacterium Infection|Unspecified diseases due to mycobacteria|mycobacterial disease|Mycobacteriosis|mycobacteriosis|Mycobacterial Infections | Mycobacterium Infections |
C0317759 | A slow-growing mycobacterium that infects the skin and subcutaneous tissues, giving rise to indolent BURULI ULCER. | Mycobacterium buruli|Mycobacterium ulcerans|Mycobacterium ulcerans (organism)|MYCOBACTERIUM ULCERANS | Mycobacterium ulcerans (bacteria) |
C0205147 | In oncology, describes the body area right around a tumor. | regional|Regional|Regional (qualifier value)|Region|Region (attribute)|REGIONAL | regional |
C1519477 | A vague term that usually refers to the phagocytic cells (macrophages) of the spleen. | Splenocytes | Splenocyte |
C0014912 | The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. | 17 beta-estradiol|17-beta-Estradiol|therapeutic estradiol|E2 - estradiol|17 beta Estradiol|Estradiolum|17β-oestradiol|17beta oestradiol|(17beta)-estra-1,3,5(10)-triene-3,17-diol|17-beta estradiol|estradiols|17-beta oestradiol|17β-estradiol|17 beta-Oestradiol|17 beta-Estradiol|17 beta Oestradiol|ESDL|cis-Estradiol|Product containing estradiol (medicinal product)|Estradiol-containing product|Estradiol 17 beta|Estradiol-17beta|Estradiol|Estradiol (E2)|Estra-1,3,5(10)-triene-3,17-diol (17beta)-|ESTRADIOL 17-BETA|beta-Estradiol|(17β)-estra-1,3,5(10)-triene-3,17-diol|Estradiol (substance)|17 beta estradiol|17beta estradiol|17β-estra-1,3,5(10)-triene-3,17-diol|Estraldine|ESTRADIOL|Oestradiol|Estradiol-17 beta|estradiol|oestradiol|17 Beta-Estradiol|Estradiol 17beta|Estradiol preparation|Estradiol Anhydrous|(17beta)-Estra-1,3,5(10)-triene-3,17-diol | estradiol |
C0005538 | Substances used in biomedicine or dentistry predominantly for their physical, as opposed to chemical, properties. | null | Biomedical and Dental Materials |
C0005538 | Substances used in biomedicine or dentistry predominantly for their physical, as opposed to chemical, properties. | null | Biomedical and Dental Materials |
C0036983 | Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include, but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status. | septic shock|Septic shock (disorder)|Septicaemic shock|Septic Shock|Septicemic shock|Sepsis-associated hypotension|Septic shock|septicemic shock|Shock, Septic|Systemic Septic Shock|SEPTIC SHOCK | Septic Shock |
C0086982 | Describes a group of molecules in a cell that work together to control one or more cell functions, such as cell division or cell death. After the first molecule in a pathway receives a signal, it activates another molecule. This process is repeated until the last molecule is activated and the cell function involved is carried out. Abnormal activation of signaling pathways can lead to cancer, and drugs are being developed to block these pathways. This may help block cancer cell growth and kill cancer cells. | signal transduction pathways|signaling pathway|signal transduction pathway|Signal Transduction Pathway|Pathway, Signal Transduction|Signaling Pathway|Signal Transduction Pathways|Pathways, Signal Transduction | Signal Transduction Pathways |
C0242966 | A systemic inflammatory response to a variety of clinical insults, characterized by two or more of the following conditions: (1) fever >38 degrees C or HYPOTHERMIA <36 degrees C; (2) TACHYCARDIA >90 beat/minute; (3) tachypnea >24 breaths/minute; (4) LEUKOCYTOSIS >12,000 cells/cubic mm or 10% immature forms. While usually related to infection, SIRS can also be associated with noninfectious insults such as TRAUMA; BURNS; or PANCREATITIS. If infection is involved, a patient with SIRS is said to have SEPSIS. | Inflammatory Response Syndrome, Systemic|Systemic inflammatory response syndrome (SIRS) NOS|SIRS - System inflammatory response syndrome|SIRS|septic syndrome|Systemic inflammatory response syndrome, unspecified|Sepsis syndrome|systemic inflammatory response syndrome|Systemic Inflammatory Response Syndrome|Sepsis Syndrome|Systemic inflammatory response syndrome (SIRS)|Syndromes, Sepsis|syndrome sepsis|Syndrome, Sepsis|sepsis syndrome|Systemic inflammatory response syndrome (disorder)|Systemic inflammatory response syndrome|Sepsis Syndromes|Sepsis syndrome (disorder)|Septic syndrome | Systemic Inflammatory Response Syndrome |
C0079904 | Ubiquitous, inducible, nuclear transcriptional activator that binds to enhancer elements in many different cell types and is activated by pathogenic stimuli. The NF-kappa B complex is a heterodimer composed of two DNA-binding subunits: NF-kappa B1 and relA. | NF-kB, Transcription Factor|Factor-Kappab, Nuclear|NF-kappaB|NF kB|nuclear factor kappa b|Immunoglobulin Enhancer Binding Protein|Nuclear Factor Kappa-B|Factor NF-kB, Transcription|nf-kb|NFKB|Enhancer-Binding Protein, Immunoglobulin|NF kappaB|Nuclear Factor NF-Kappa-B|Nuclear Factor-Kappab|Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-Cells|Transcription Factor NF-kB|Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells|NF-kappa B|NF-Kappa-B|Transcription Factor NF kB|Nuclear Factor Kappab|nf kappab|kappa B Enhancer Binding Protein|Nuclear Factor Kappa B|Nuclear Factor kappa B|nf kb|b factor kappa nuclear|NF-KappaB|nf-kappa b|Nuclear Transcription Factor NF-kB|nuclear factor kappa b (nf-kb)|NF-Kappa B|nuclear factor kappa beta|Immunoglobulin Enhancer-Binding Protein|Nuclear Factor of Kappa Light Chain Gene Enhancer in B Cells|NF-kB | NF-kappa B |
C0441509 | A destruction of tissue by means that results in condensation of protein material | Coagulation (procedure)|coagulation therapy|Coagulation - action|Coagulation - action (qualifier value)|Coagulation|coagulations|coagulation | Coagulation procedure |
C0002986 | An X-linked inherited metabolic disease caused by a deficiency of lysosomal ALPHA-GALACTOSIDASE A. It is characterized by intralysosomal accumulation of globotriaosylceramide and other GLYCOSPHINGOLIPIDS in blood vessels throughout the body leading to multi-system complications including renal, cardiac, cerebrovascular, and skin disorders. | FABRY DISEASE|Anderson-Fabry disease|alpha-Galactosidase A Deficiency|fabry's disease|Ceramide trihexosidase deficiency|Deficiency, GLA|HEREDITARY DYSTOPIC LIPIDOSIS|Thesaurismosis lipoidica|Fabry syndrome|Deficiency of melibiase|Hereditary dystopic lipidosis|fabri disease|Fabry's Disease|thesaurismosis hereditaria|Ceramide lactoside lipidosis|Angiokeratoma corporis diffusum universale|Angiokeratoma Diffuse|alpha-Galactosidase A Deficiency Disease|disease fabry's|Fabry disease|Lactosyl ceramidosis|Diffuse Angiokeratoma|CERAMIDE TRIHEXOSIDE LIPOIDOSIS <FABRYS DISEASE>|Angiokeratoma Corporis Diffusum|Deficiency of alpha-galactosidase (disorder)|Ruiter-Pompen syndrome|Fabry's disease|Angiokeratoma, Diffuse|CERAMIDE TRIHEXOSIDE LIPOIDOSIS FABRYS DISEASE|ceramide trihexosidosis|anderson-fabry disease|Fabry Disease|ALPHA-GALACTOSIDASE A DEFICIENCY|Thesaurismosis hereditaria|Fabry's disease (disorder)|alpha-Galactosidase-A deficiency|alpha Galactosidase A Deficiency Disease|disease fabry|ANDERSON-FABRY DISEASE|fabry disease|FABRY'S DISEASE|Alpha-galactosidase A deficiency|alpha Galactosidase A Deficiency|Alpha-Galactosidase A Deficiency|GLA deficiency|GLA DEFICIENCY|Sweeley-Klionsky disease|Ceramide Trihexosidase Deficiency|GLA Deficiency|Angiokeratoma corporis diffusum|Deficiency, Ceramide Trihexosidase|ceramide trihexosidase deficiency|CERAMIDE TRIHEXOSIDASE DEFICIENCY|ANGIOKERATOMA CORPORIS DIFFUSUM|Anderson Fabry Disease|angiokeratoma corporis diffusum|Cardiovasorenal syndrome|Lipidosis, Hereditary Dystopic|Deficiency, alpha-Galactosidase A|fabrys disease|Anderson-Fabry Disease|Trihexosidase deficiency disease|alpha galactosidase deficiency|Hereditary Dystopic Lipidosis|Deficiency of alpha-galactosidase | Fabry Disease |
C0200760 | measurement of changes in form or structure of an organism or any of its parts. | Morphometric analysis (procedure)|Morphometry|Morphometric analysis|morphometric analysis|Morphometry, NOS|morphometry|Morphometric analysis, NOS | Morphometric analysis |
C0596995 | Embryonic (precursor) cells of the myogenic lineage that develop from the MESODERM. They undergo proliferation, migrate to their various sites, and then differentiate into the appropriate form of myocytes (MYOCYTES, SKELETAL; MYOCYTES, CARDIAC; MYOCYTES, SMOOTH MUSCLE). | Muscle Cell, Precursor|Myoblasts|myoblasts|Muscle Cell, Embryonic|Myoblast|Muscle Cells, Embryonic|Muscle Cells, Precursor|Precursor Muscle Cell|Embryonic Muscle Cells|myoblast|Embryonic Muscle Cell|Precursor Muscle Cells | Myoblasts |
C0165465 | null | RS-15385-197 | RS 15385-197 |
C0165465 | null | RS-15385-197 | RS 15385-197 |
C0001431 | A small tumor of the anterior lobe of the pituitary gland whose cells stain with basic dyes. It may give rise to excessive secretion of ACTH, resulting in CUSHING SYNDROME. (Dorland, 27th ed) | adenoma, basophilic, pituitary|Mucoid cell adenoma|Adenomas, Basophil|pituitary basophilic adenoma|Basophilic Pituitary Gland Adenoma|Pituitary Gland Basophil Adenoma|Adenomas, Basophilic|Basophil adenoma (morphologic abnormality)|Basophil adenoma|basophilic adenoma, pituitary|Adenoma, Basophilic|Basophil Adenomas|Mucoid Cell Adenoma|Basophilic Adenoma|Basophilic Adenomas|Basophil Adenoma | Adenoma, Basophil |
C0001431 | A small tumor of the anterior lobe of the pituitary gland whose cells stain with basic dyes. It may give rise to excessive secretion of ACTH, resulting in CUSHING SYNDROME. (Dorland, 27th ed) | adenoma, basophilic, pituitary|Mucoid cell adenoma|Adenomas, Basophil|pituitary basophilic adenoma|Basophilic Pituitary Gland Adenoma|Pituitary Gland Basophil Adenoma|Adenomas, Basophilic|Basophil adenoma (morphologic abnormality)|Basophil adenoma|basophilic adenoma, pituitary|Adenoma, Basophilic|Basophil Adenomas|Mucoid Cell Adenoma|Basophilic Adenoma|Basophilic Adenomas|Basophil Adenoma | Adenoma, Basophil |
C0017263 | Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. | Gene Regulation Process|Genetic regulation|regulation of gene expression|genetic regulation|Expression Regulation, Gene|Gene Action Regulation|Gene Regulation|genes regulation|genetic control|gene expression regulation|gene regulation|genetics regulations|Gene Expression Regulation|Regulation, Gene Action|Regulation, Gene Expression|Gene Expression Alteration|Regulation of Gene Expression | Gene Expression Regulation |
C0297666 | null | SB-203580|SB203580 | SB 203580 |
C0251991 | A morpholine-based inhibitor of phosphatidylinositol 3-kinase (PI3K) and the bromodomain and extra-terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, the PI3K/BET inhibitor LY294002 specifically targets and binds to both PI3K and the acetylated lysine recognition motifs in the bromodomains of BET proteins. Inhibition of PI3K activity inhibits the PI3K/AKT kinase signaling pathway. This may result in inhibition of growth and survival for tumor cells in which the PI3K-mediated signaling pathway is overactivated. Inhibition of BET proteins prevents their interaction with acetylated histones, disrupts chromatin remodeling and inhibits the expression of oncogenic drivers that are important for cell proliferation and survival, which together may lead to an inhibition of proliferation in BET-overexpressing tumor cells. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators and play an important role during development and cellular growth. In tumor cells, BET proteins play a key role in the regulation of oncogene transcription and tumor cell proliferation. | LY-294002|LY294002|LY 294002|PI3K/BET Inhibitor LY294002 | LY 294002 |
C0596997 | The developmental sequence of events leading to the formation of adult skeletal muscle tissue. The main events are: the fusion of myoblasts to form myotubes that increase in size by further fusion to them of myoblasts, the formation of myofibrils within their cytoplasm and the establishment of functional neuromuscular junctions with motor neurons. At this stage they can be regarded as mature muscle fibers. [GOC:mtg_muscle] | Skeletal Muscle Tissue Development|myogenesis|Myogenesis|skeletal muscle tissue development | Myogenesis |
C0440429 | null | Rabbit epithelium|Rabbit epithelium (substance) | Rabbit epithelium |
C0009758 | The mucous membrane that covers the posterior surface of the eyelids and the anterior pericorneal surface of the eyeball. | Wall of conjunctival sac|Conjunctiva, NOS|Tunica Conjunctiva|conjunctiva|Tunica conjunctiva|Conjunctivas|Conjunctival|Conjunctival structure (body structure)|Conjunctiva|CONJUNCTIVA|Conj - Conjunctiva|Conjunctival structure | conjunctiva |
C0389847 | null | SLIGRL|Ser-Leu-Ile-Gly-Arg-Leu | seryl-leucyl-isoleucyl-glycyl-arginyl-leucine |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.